Quality of Life in Asthma and Rhinitis Allergic With Singulair (0476-365)

Phase 4CompletedNCT00380705

Organon and Co91 enrolled

Overview

Allow physicians not familiar with anti-leukotriene based therapy to test it

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Asthma Rhinitis Allergic

Interventions

MK0476, Singulair, montelukast sodium / Duration of Treatment: 8 WeeksDRUG

Eligibility

Sex: ALLMin age: 6 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Establish diagnosis of mild to moderate chronic asthma and/or allergic rhinitis currently on treatment * Voluntary acceptance to participate in the study Exclusion Criteria: * Patients with cystic fibrosis * Patients with known hypersensitivity to singulair or any of its components * Patients with severe chronic asthma

Outcomes

Primary Outcomes

Quality of life measures

Secondary Outcomes

Nocturnal wake up, work or school absences, physical activity and recurrence of asthma and/or rhinitis

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.